Greg Mayes, the new CEO of Reunion Neuroscience (TSX:REUN, Nasdaq:REUN), has a more traditional drug development background than many executives in the psychedelic space. He had a successful foray into epilepsy at a company known as Engage Therapeutics. Founded in 2017, Engage was picked up by UCB in 2020. While Mayes’ background in pharma dates…
Reunion Neuroscience names new CEO to guide development of psychedelic depression therapy
Formerly known as Field Trip Discovery, Reunion Neuroscience (TSX:REUN, Nasdaq:REUN) has announced the appointment of Greg Mayes as its new president and CEO. Mayes will first focus on completing the company’s Phase 1 clinical trial of its lead asset, RE-104 (formerly FT-104), for postpartum and treatment-resistant depression. Mayes had held several senior executive roles at…